The post Big, Beautiful Bill Finds Its Opponents appeared first on Reason.com.

US health officials met with with Walmart Inc. and other retailers this week as part of an effort to help Americans get their ...

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Wall Street's main indexes opened subdued on Monday as investors awaited Iran's possible response to U.S. airstrikes on its ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

U.S. stock indexes rallied on Monday as investors looked past worries of potential crude supply disruptions after the United ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.